Coadministration of epidermal growth factor and growth hormone releasing peptide-6 improves clinical recovery in experimental autoimmune encephalitis.

Content Provider	Semantic Scholar
Author	Barco, Diana García Del Montero, E. Coro-Antich, Rosa María Brown, Enma Suárez-Alba, José López, Laura Álvarez Subirós, Nelvys Berlanga, Jorge García
Copyright Year	2011
Abstract	PURPOSE Multiple sclerosis is a complex and devastating autoimmune disease of the central nervous system. Up to now, a constellation of candidate drugs have been evaluated with no major success. Experimental Autoimmune Encephalitis (EAE) is the animal counterpart that reproduces critical features of the human MS process. The aim of the present work is to study a possible therapeutic effect of epidermal growth factor (EGF) and growth hormone releasing peptide-6 (GHRP(6)) coadministration in mild and severe EAE. METHODS Mild and severe forms of EAE were generated immunizing rats and mice with xenogeneic spinal cord homogenate and with the encephalitogenic peptide MOG(p35-35), respectively. EGF and GHRP(6) alone or combined were administered in therapeutic and prophylactic schedules. A clinical score was established to follow-up the animals during the disease period. Malondialdehyde (MDA) serum concentration and insulin like growth factor-1 (IGF-1) relative level from brain tissue were determined. RESULTS Only the combined EGF+GHRP(6) therapy reduced the clinical score in mild as well in severe EAE forms. The combination also improved the survival rate in nearly 100% of the severe EAE animals. In addition to these effects, there was an increase in the brain IGF-1 transcript and a decrease of serum MDA. CONCLUSIONS EGF+GHRP(6) proved to be effective in improving the natural course of both mild and severe EAE. Accordingly, the treatment reduces inflammatory infiltration and microvascular damage, which may be associated to the attenuation of the lipid peroxidation process and the transcriptional enhancement of IGF-1, a major pro-survival factor for brain cells.
Starting Page	609
Ending Page	610
Page Count	2
File Format	PDF HTM / HTML
Alternate Webpage(s)	http://content.iospress.com/download/restorative-neurology-and-neuroscience/rnn29ai?id=restorative-neurology-and-neuroscience/rnn29ai
PubMed reference number	21697595v1
Alternate Webpage(s)	https://doi.org/10.3233/RNN-2011-0595
DOI	10.3233/RNN-2011-0595
Journal	Restorative neurology and neuroscience
Volume Number	29
Issue Number	4
Language	English
Access Restriction	Open
Subject Keyword	3,4-Methylenedioxyamphetamine Autoimmune Diseases CNS disorder Condoms, Unspecified Experimental Autoimmune Encephalomyelitis Follow-Up Report Growth Factor Hashimoto's encephalitis Herpes encephalitis Homogenate Inflammatory Bowel Diseases Lipid Peroxidation Malondialdehyde Multiple Sclerosis Neuritis, Autoimmune, Experimental Schedule (document type) Somatomedins Spinal Cord Transcript Transcription, Genetic
Content Type	Text
Resource Type	Article